The 2022 guidelines of the American Diabetes Association (ADA) and the Kidney Disease Improving Global Outcomes (KDIGO) for the treatment of patients with DKD advise the use of finerenone, which is a nonsteroidal mineralocorticoid receptor antagonist (MRA), in patients who have increased albuminuria despite treatment with an ACEi/ARB and SGLT2 inhibitor [114,115]. The gene discussed is NR3C2; the disease is diabetic kidney disease.